Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor

Basit Öğe Kaydı
dc.contributor.authorLiabeuf, Sophie
dc.contributor.authorPesic, Vesna
dc.contributor.authorSpasovski, Goce
dc.contributor.authorMaciulaitis, Romaldas
dc.contributor.authorBobot, Mickael
dc.contributor.authorFarinha, Ana
dc.contributor.authorWagner, Carsten A.
dc.contributor.authorUnwin, Robert J.
dc.contributor.authorCapasso, Giovambattista
dc.contributor.authorBumblyte, Inga Arune
dc.contributor.authorHafez, Gaye
dc.date.accessioned2023-11-07T12:29:16Z
dc.date.available2023-11-07T12:29:16Z
dc.date.issued2023en_US
dc.departmentFakülteler, Eczacılık Meslek Bilimleri Bölümü, Farmakoloji Ana Bilim Dalıen_US
dc.description.abstractPeople living with chronic kidney disease (CKD) frequently suffer from mild cognitive impairment and/or other neurocognitive disorders. This review in two parts will focus on adverse drug reactions resulting in cognitive impairment as a potentially modifiable risk factor in CKD patients. Many patients with CKD have a substantial burden of comorbidities leading to polypharmacy. A recent study found that patients seen by nephrologists were the most complex to treat because of their high number of comorbidities and medications. Due to polypharmacy, these patients may experience a wide range of adverse drug reactions. Along with CKD progression, the accumulation of uremic toxins may lead to blood-brain barrier (BBB) disruption and pharmacokinetic alterations, increasing the risk of adverse reactions affecting the central nervous system (CNS). In patients on dialysis, the excretion of drugs that depend on kidney function is severely reduced such that adverse and toxic levels of a drug or its metabolites may be reached at relatively low doses, unless dosing is adjusted. This first review will discuss how CKD represents a risk factor for adverse drug reactions affecting the CNS via (i) BBB disruption associated with CKD and (ii) the impact of reduced kidney function and dialysis itself on drug pharmacokinetics.en_US
dc.identifier.citationLiabeuf, S., Pesic, V., Spasovski, G., Maciulaitis, R., Bobot, M., Farinha, A., ... & Hafez, G. (2023). Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease (CKD) as a risk factor. Clinical Kidney Journal.en_US
dc.identifier.issn2048-8505
dc.identifier.issn2048-8513
dc.identifier.scopus2-s2.0-85184750461
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://hdl.handle.net/20.500.12939/4215
dc.identifier.wosWOS:001076450600001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorHafez, Gaye
dc.language.isoen
dc.relation.ispartofClinical Kidney Journal
dc.relation.isversionof10.1093/ckj/sfad241en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdverse drug reactionsen_US
dc.subjectChronic kidney diseaseen_US
dc.subjectCognitive impairmenten_US
dc.subjectDrug prescriptionen_US
dc.titleDrugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
sfad241.pdf
Boyut:
1.05 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu